Moleculin

200 articles with Moleculin

• Moleculin to Report Full Year 2022 Financial Results on March 22, 2023 and Host Conference Call and Webcast

  3/15/2023

  Moleculin Biotech, Inc. today announced that it will report its financial results for the full year December 31, 2022 after market close on Wednesday, March 22, 2023.

• Moleculin to Present at the Oppenheimer 33rd Annual Healthcare Conference

  3/13/2023

  Moleculin Biotech, Inc. today announced that Jonathan P. Foster, Chief Financial Officer of Moleculin, will present at the virtual Oppenheimer 33rd Annual Healthcare Conference on Tuesday, March 14, 2023 at 12:40 PM ET.

• Moleculin Announces it Has No Exposure to Silicon Valley Bank Situation

  3/13/2023

  Moleculin Biotech, Inc. today announced that it is aware that the Federal Deposit Insurance Corp. has taken control of Silicon Valley Bank (SVB) due to liquidity concerns.

• Moleculin to Present at the Virtual Investor 2023 Companies to Watch Event

  1/5/2023

  Moleculin Biotech, Inc.  today announced that Walter Klemp , President and Chief Executive Officer of Moleculin, will present at the Virtual Investor 2023 Companies to Watch Event on Tuesday, January 17, 2023 at 9:00 AM ET.

• Moleculin Receives Approval in Italy to Conduct Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)

  12/21/2022

  Moleculin Biotech, Inc. today announced it has received approval from the Agenzia Italiana del Farmaco and the Istituto Superiore di Sanità for its Phase 1/2 trial evaluating Annamycin in combination with Cytarabine (Ara-C) in the treatment of subjects with AML who are refractory to or relapsed after induction therapy (MB-106).

• Moleculin Granted FDA Fast Track Designation of WP1122 for the Treatment of Glioblastoma Multiforme

  12/7/2022

  Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the U.S. Food and Drug Administration ("FDA") has granted Fast Track designation of WP1122 for the treatment of Glioblastoma Multiforme ("GBM").

• Moleculin Reports Third Quarter 2022 Financial Results and Provides Pipeline Update

  11/10/2022

  Moleculin Biotech, Inc., a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, reported its financial results for the quarter ended September 30, 2022 and provided a pipeline update.

• Moleculin to Report Third Quarter 2022 Financial Results on November 10, 2022 and Host Inaugural Quarterly Conference Call and Webcast

  11/7/2022

  Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it will report its financial results for the quarter ended September 30, 2022 on Thursday, November 10th.

• Moleculin Provides Update on Second Multiple Ascending Dose (MAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK

  10/14/2022

  Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today provided an update on the preliminary results from the second multiple ascending dose (MAD) cohort of the Company's first-in-human Phase 1a study of WP1122.

• Moleculin Biotech WP1122 Portfolio Compound, WP1096, Selected for NIAID-Funded Animal Studies as Novel Potential Antiviral

  9/27/2022

  Moleculin Biotech, Inc. announced its WP1096 molecule will be evaluated in animal studies through the preclinical services offered by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

• Moleculin Biotech to Present at the Virtual Investor Innovations in Acute Myeloid Leukemia (AML) Spotlight Event

  9/23/2022

  Moleculin Biotech, Inc. oday announced that Walter V. Kemp, Founder, President, CEO and Chairman, and Wolfram C. M. Dempke, MD, PhD, MBA, European Chief Medical Officer of Moleculin will participate in the Virtual Investor Innovations in Acute Myeloid Leukemia Spotlight Event on Wednesday, September 28, 2022 at 11:00 AM ET.

• Moleculin Selected to Present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care

  9/8/2022

  Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), today announced that members of management will virtually present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care being held at the Roswell Park Comprehensive Cancer Center in Buffalo, NY September 8-10, 2022.

• Moleculin to Present at the H.C. Wainwright 24th Annual Global Investment Conference

  9/7/2022

  Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), today announced that Walter Klemp, President and Chief Executive Officer of Moleculin, will present at the H.C. Wainwright 24th Annual Global Investment Conference being held in New York, NY and virtually on September 12-14, 2022.

• Moleculin Receives FDA Orphan Drug Designation of WP1122 for the Treatment of Glioblastoma Multiforme

  9/6/2022

  Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), today announced that the U.S. Food and Drug Administration ("FDA") has granted Orphan Drug Designation of WP1122 for the treatment of Glioblastoma Multiforme ("GBM").

• Moleculin Announces Completion of Third Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK

  8/19/2022

  Moleculin Biotech, Inc. today reported preliminary results from the third cohort of the Company's first-in-human Phase 1a study of WP1122.

• Moleculin Reports Second Quarter 2022 Financial Results and Provides Programs Update

  8/15/2022

  Moleculin Biotech, Inc. today reported its financial results for the quarter ended June 30, 2022.

• Moleculin Concludes Phase 1b and Opens Recruitment in Phase 2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases

  7/28/2022

  Moleculin Biotech, Inc. today announced it has completed the safety review of the fourth cohort in a dose escalation clinical trial evaluating Annamycin for the treatment of soft tissue sarcoma (STS) lung metastases, thus concluding the Phase 1b portion of its U.S. Phase 1b/2 clinical trial.

• 

  Clinical Catch-Up: Vertex, Ayala, Arrowhead, Dyne & More

  7/11/2022

  Ayala announced positive data for its desmoid tumor treatment, while Vertex and Dyne announced the FDA had lifted the hold on their clinical studies. 

• Moleculin Announces Completion of Second Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK

  7/8/2022

  Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today reported preliminary results from the second cohort of the Company's first-in-human Phase 1a study of WP1122.

• Moleculin Announces Completion of First Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK

  6/16/2022

  Preliminary results of first cohort in the first-in-human Phase 1a allows Company to proceed to 16 mg/kg dose of WP1122 in second cohort toward establishing maximum tolerated dose (MTD).